Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma
Authors:
Open Access
- 22 September 2014
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 34 (29) , 3770-3779
Abstract
Medulloblastoma (MB) is a highly malignant brain tumor that occurs primarily in children. Although surgery, radiation and high-dose chemotherapy have led to increased survival, many MB patients still die from their disease, and patients who survive suffer severe long-term side effects as a consequence of treatment. Thus, more effective and less toxic therapies for MB are critically important. Development of such therapies depends in part on identification of genes that are necessary for growth and survival of tumor cells. Survivin is an inhibitor of apoptosis protein that regulates cell cycle progression and resistance to apoptosis, is frequently expressed in human MB and when expressed at high levels predicts poor clinical outcome. Therefore, we hypothesized that Survivin may have a critical role in growth and survival of MB cells and that targeting it may enhance MB therapy. Here we show that Survivin is overexpressed in tumors from patched (Ptch) mutant mice, a model of Sonic hedgehog (SHH)-driven MB. Genetic deletion of survivin in Ptch mutant tumor cells significantly inhibits proliferation and causes cell cycle arrest. Treatment with small-molecule antagonists of Survivin impairs proliferation and survival of both murine and human MB cells. Finally, Survivin antagonists impede growth of MB cells in vivo. These studies highlight the importance of Survivin in SHH-driven MB, and suggest that it may represent a novel therapeutic target in patients with this disease.Keywords
This publication has 70 references indexed in Scilit:
- Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of SurvivinMolecular & Cellular Proteomics, 2012
- Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastomaNeuro-Oncology, 2012
- Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanomaCancer Immunology, Immunotherapy, 2012
- Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastomaNeuro-Oncology, 2012
- Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivinOncogene, 2011
- Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose StudyClinical Cancer Research, 2010
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449New England Journal of Medicine, 2009
- Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell lineJournal of Cell Biology, 2008
- Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem CellsCancer Cell, 2008
- Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cellsBritish Journal of Cancer, 2008